Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the first quarter ended March 31, 2020 and provided a corporate update. Identified TISvopra predictive biomarker for Phase 2 SELECT trial: In February 2020, Jounce presented new data identifying the predictive biomarker associated with vopratelimab patient selection, known as TISvopra, a baseline RNA signature with a threshold optimized for the prediction of the emergence of ICOS hi CD4 T cells which is expected to predict for both vopratelimab and PD-1 activity.

CAMBRIDGE, Mass., Feb. 21, 2020 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.

- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019.

Shares of Jounce Therapeutics (NASDAQ:JNCE) were unaffected at $5.34 after the company reported Q1 results.Quarterly Results Earnings per share were down 105.26% year over year to ($0.78), which missed the estimate of ($0.57).Revenue of $0 less by 100.00% year over year, which missed the estimate of $1,670,000.Looking Ahead Jounce Therapeutics hasn't issued any earnings guidance for the time being.Jounce Therapeutics hasn't issued any revenue guidance for the time being.Details Of The Call Date: May 06, 2020View more earnings on JNCETime: 07:00 AM ETWebcast URL: https://edge.media-server.com/mmc/p/7ohau932Technicals Company's 52-week high was at $10.0052-week low: $2.79Price action over last quarter: Up 18.14%Company Profile Jounce Therapeutics Inc is a clinical stage immunotherapy company. The company is dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company's strategy is to create immunotherapies targeting a variety of the diverse cellular components of the immune system, as well as non-immune cells resident within the tumor, all of which can vary greatly among tumors within and across indications. This may provide benefit to patients with tumors across the spectrum from highly inflamed, or hot, to poorly inflamed, or cold, and especially those not well served by current therapies. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody.See more from Benzinga * Venator Materials: Q1 Earnings Insights * Stocks That Hit 52-Week Lows On Tuesday * Portola Pharmaceuticals: P/E Ratio Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

New Strong Buy Stocks for February 27th

NEW YORK, NY / ACCESSWIRE / February 27, 2020 / Jounce Therapeutics, Inc. (NASDAQ:JNCE) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 27, 2020 ...

Speaking on today's call will be our CEO and President, Dr. Rich Murray, who will discuss our pipeline progress and key milestones; followed by our CMO, Dr. Beth Trehu, who will provide an update on our clinical activities; and lastly, our CFO, Kim Drapkin, will review our first quarter financial results. Before we begin, I would like to remind everyone that today's discussion will include statements about our future expectations, plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.

Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Robert Iannone, M.D., M.S.C.E., to its board of directors. “Rob brings enormous value to the Jounce board of directors as we move further into the clinic and continue to broaden our pipeline of discovery programs,” said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. Dr. Iannone serves as the executive vice president, research and development of Jazz Pharmaceuticals, which he joined in May 2019.

CAMBRIDGE, Mass., Feb. 26, 2020 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.

CAMBRIDGE, Mass., May 15, 2020 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) missed earnings with its latest first-quarter results, disappointing...

How far off is Jounce Therapeutics, Inc. (NASDAQ:JNCE) from its intrinsic value? Using the most recent financial data...

Is (JNCE) Outperforming Other Medical Stocks This Year?

CAMBRIDGE, Mass., April 29, 2020 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.

In 2014 Rich Murray was appointed CEO of Jounce Therapeutics, Inc. (NASDAQ:JNCE). This analysis aims first to contrast...

Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.

Jounce Therapeutics (NASDAQ:JNCE) has had a rough three months with its share price down 30%. However, a closer look...

CAMBRIDGE, Mass., Jan. 09, 2020 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies.

Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced new data on the identification of the predictive biomarker to be used for patient selection in the SELECT clinical trial of vopratelimab (vopra), in addition to a research collaboration with NanoString (NSTG). The new data introduces TISvopra, a baseline RNA signature with a threshold optimized for the emergence of ICOS hi CD4 T cells, a vopratelimab pharmacodynamic biomarker not associated with PD-1 inhibitor therapy.